Latest Research And Development News

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

Syntara Limited has made significant strides in its clinical pipeline, launching new trials and receiving key regulatory designations, positioning 2026 as a pivotal year for the company.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Knosys reports steady revenue growth and a strategic partnership to upgrade its GreenOrbit platform, while accelerating development of its AI-powered Libero X library solution for a global launch next year.

Zeotech Limited has made significant strides in advancing its Toondoon Kaolin Project mining readiness and secured key partnerships to commercialise its AusPozz™ metakaolin product, validated by independent testing.

Bass Oil Limited reported a 7.9% rise in quarterly oil sales revenue and a 7.4% increase in production, alongside a pivotal gas sales agreement with Origin Energy for the Vanessa gas field, pending regulatory approval.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

Acrux Limited reports solid revenue growth and increased cash reserves in the December quarter, driven by expanding its topical generics portfolio in the US and strategic moves into female Hormone Replacement Therapy.

Silver Mines Limited has reported its best-ever drilling results at the Bowdens Silver Project in NSW while navigating a complex regulatory redetermination process. Exploration advances continue across its Australian and US projects, supported by a strong cash position.